Immersive Virtual Reality for the Management of Chemotherapy-Induced Distress in Patients With Cancer
JCO Oncology Advances · 2026-10 · 3 (4)
DOI: 10.1200/oa-25-00217 ↗Abstract
Purpose Patients with cancer face high levels of distress, anxiety, depression, and pain, often exacerbated during chemotherapy. This pilot trial evaluated the preliminary effect of immersive virtual reality (VR) on these symptoms compared with standard of care (SOC). Methods In this two-arm randomized controlled trial, participants were allocated 1:1 to a one-time 15-minute VR session or SOC referring to the participant's choice of available activity like watching television during chemotherapy. The primary objective was to assess the effect of VR on distress levels compared with the SOC group. Secondary objectives included assessing the preliminary effects of VR on anxiety, pain, and depressive symptoms, compared with the SOC group. Validated questionnaires were administered to both groups before and after the intervention. Outcomes were analyzed using analysis of covariance models adjusting for baseline values, age, and sex. SAS Studio 3.7 and R version 4.2 were used. Results Sixty-eight participants completed the study (33 VR, 35 SOC). After adjustment for baseline distress, age, and sex, the VR group had significantly lower postintervention distress scores than the SOC group (adjusted mean difference 1.4 points, 95% CI, 0.34 to 2.45; P = .0102). The VR group had significantly lower postintervention depression and pain scores than the SOC group (adjusted mean differences: 1.14, P = .0055; and 1.5, P = .0032, respectively). Adjusted anxiety scores were lower with VR than SOC but did not reach statistical significance (mean difference 1.76; P = .0815). Conclusion VR is a safe, innovative immersive intervention with the potential to reduce distress, pain, and depressive symptoms during chemotherapy. Larger longitudinal studies are needed to determine the optimal duration and frequency needed to reduce anxiety and maximize the durability of its effects.
EUVIMED